Investors & Media

What’s new.

Press releases

Press releases.

March 25th 2025

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

March 20th 2025

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

January 31st 2025

Immutep Quarterly Activities Report Q2 FY25

more

Investor updates

Investor updates.

November 26th 2024

Investor Update - November 2024

February 21st 2024

Investor Update - February 2024

August 18th 2023

Investor Update - August 2023

more

Analyst reports

Analyst reports.

March 4th 2025

Canaccord Genuity - 1H25 model update: All eyes on next HNSCC update; Maintain BUY, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

March 3rd 2025

Baird - Transferring Coverage: Compelling Opportunity for Efti in Phase 3 NSCLC; Rated OP, US$7 PT (Analyst: Colleen Kusy)

For a copy of this research report please contact your Baird advisor

February 26th 2025

Jefferies - 1HFY25: Did It Again; Buy, Raise PT to A$2.10 (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

more